ReviewDrug and alcohol dependence reports2023
History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder.
Review in Drug and alcohol dependence reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials.CNS drugs · 2026Pooled it
- Clinical outcomes associated with drug-drug interactions involving buprenorphine: a systematic review.Addiction science & clinical practice · 2026Pooled it
- A Single-Dose Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Monthly Extended-Release Buprenorphine at Alternative Injection Locations in Adult Participants with Opioid Use Disorder.Clinical drug investigation · 2024Trial
- Co-treating opioid and alcohol use disorders in the United States, 1960-2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era.Drug and alcohol dependence reports · 2026Review
- Impact of Substance Use Disorder Curriculum and X-Waiver Training on Emergency Medicine Residents.The western journal of emergency medicine · 2026Article
- Reducing Buprenorphine Misinformation as a Strategy to Improve Adoption in Primary Care.Substance use & misuse · 2026Article
- Evaluation of opioid requirements in mechanically ventilated patients taking buprenorphine/naloxone prior to admission.Journal of critical care · 2026Article
- Engaging veterans in the development of mobile health interventions to support medication treatment for opioid use disorder.Frontiers in digital health · 2026Article
- Metabolic Cage Analysis of Surgically Catheterized C57BL/6J Mice (Mus musculus) Treated with Carprofen and Sustained-Release Buprenorphine.Journal of the American Association for Laboratory Animal Science : JAALAS · 2025Article
- SubgroupTE: Advancing Treatment Effect Estimation with Subgroup Identification.ACM transactions on intelligent systems and technology · 2025Article
- Long-acting injectables for the treatment of substance use disorder: a look ahead.Expert opinion on drug delivery · 2025Article
- Social Listening for Patient Experiences With Stopping Extended-Release Buprenorphine: Content Analysis of Reddit Messages.Journal of medical Internet research · 2025Article
- The impact of psychostimulant use on office based buprenorphine treatment retention.Harm reduction journal · 2025Article
- Buprenorphine: Applications in Oncology and Palliative Care.Clinical journal of oncology nursing · 2025Article
- Differential Effects of Prenatal Buprenorphine and Methadone on Postnatal Growth and Gene Expression in the Nucleus Accumbens.Developmental psychobiology · 2025Article
- Evolution of the substance use landscape: Implications for contingency management.Journal of applied behavior analysis · 2025Review
- Advancing research translation in addiction and pain: A portfolio analysis of the NIH HEAL initiative.Journal of clinical and translational science · 2025Article
- Primary care professionals' perspectives on tailoring buprenorphine training for rural practice.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2024Article
- Nor-LAAM loaded PLGA microparticles for treating opioid use disorder.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Federal Impacts on Buprenorphine Prescribing in Washington State, 2012 to 2022.American journal of public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Buprenorphine-based medications were first approved by the United States Food and Drug Administration in 2002 for the treatment of opioid dependence, or opioid use disorder (OUD) as the condition is presently known. This regulatory milestone was the outcome of 36 years of research and development, which also led to the development and approval of several other new buprenorphine-based medications. In this short review, we first describe the discovery and early development stages of buprenorphine. Second, we review key steps that led to the development of buprenorphine as a drug product. Third, we explain the regulatory approval of several buprenorphine-based medications for the treatment of OUD. We also discuss these developments in the context of the evolution of regulations and policies that have progressively improved OUD treatment availability and efficacy, although challenges remain in removing system-level, provider-level, and local-level barriers to quality treatment, to integrating OUD treatment into routine care and other settings, to reducing disparities in access to treatment, and to optimizing person-centered outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.